Ensysce Biosciences Stock Net Income
| ENSC Stock | USD 0.86 0.03 3.37% |
As of the 24th of January, Ensysce Biosciences shows the Standard Deviation of 5.09, variance of 25.9, and Mean Deviation of 3.75. Ensysce Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Ensysce Biosciences Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | (5.26) | (5.52) | |
| Net Income Per E B T | 0.90 | 0.94 |
Ensysce | Net Income | Build AI portfolio with Ensysce Stock |
Latest Ensysce Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Ensysce Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ensysce Biosciences financial statement analysis. It represents the amount of money remaining after all of Ensysce Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ensysce Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ensysce Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.99 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ensysce Net Income Regression Statistics
| Arithmetic Mean | (4,943,395) | |
| Geometric Mean | 427,565 | |
| Coefficient Of Variation | (185.74) | |
| Mean Deviation | 6,797,995 | |
| Median | (31,193) | |
| Standard Deviation | 9,181,789 | |
| Sample Variance | 84.3T | |
| Range | 31.3M | |
| R-Value | (0.53) | |
| Mean Square Error | 64.3T | |
| R-Squared | 0.29 | |
| Significance | 0.03 | |
| Slope | (971,219) | |
| Total Sum of Squares | 1348.9T |
Ensysce Net Income History
Other Fundumenentals of Ensysce Biosciences
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ensysce Biosciences Net Income component correlations
Ensysce Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ensysce Biosciences is extremely important. It helps to project a fair market value of Ensysce Stock properly, considering its historical fundamentals such as Net Income. Since Ensysce Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ensysce Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ensysce Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.35) | Revenue Per Share | Quarterly Revenue Growth (0.86) | Return On Assets | Return On Equity |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ensysce Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ensysce Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ensysce Biosciences.
| 10/26/2025 |
| 01/24/2026 |
If you would invest 0.00 in Ensysce Biosciences on October 26, 2025 and sell it all today you would earn a total of 0.00 from holding Ensysce Biosciences or generate 0.0% return on investment in Ensysce Biosciences over 90 days. Ensysce Biosciences is related to or competes with Soligenix, Oragenics, Kala Pharmaceuticals, Xenetic Biosciences, AIM ImmunoTech, Vyne Therapeutics, and Kazia Therapeutics. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for... More
Ensysce Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ensysce Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ensysce Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.31) | |||
| Maximum Drawdown | 23.86 | |||
| Value At Risk | (10.78) | |||
| Potential Upside | 5.94 |
Ensysce Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ensysce Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ensysce Biosciences' standard deviation. In reality, there are many statistical measures that can use Ensysce Biosciences historical prices to predict the future Ensysce Biosciences' volatility.| Risk Adjusted Performance | (0.21) | |||
| Jensen Alpha | (1.58) | |||
| Total Risk Alpha | (1.99) | |||
| Treynor Ratio | (1.48) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ensysce Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ensysce Biosciences January 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.21) | |||
| Market Risk Adjusted Performance | (1.47) | |||
| Mean Deviation | 3.75 | |||
| Coefficient Of Variation | (338.42) | |||
| Standard Deviation | 5.09 | |||
| Variance | 25.9 | |||
| Information Ratio | (0.31) | |||
| Jensen Alpha | (1.58) | |||
| Total Risk Alpha | (1.99) | |||
| Treynor Ratio | (1.48) | |||
| Maximum Drawdown | 23.86 | |||
| Value At Risk | (10.78) | |||
| Potential Upside | 5.94 | |||
| Skewness | 0.1222 | |||
| Kurtosis | 0.7324 |
Ensysce Biosciences Backtested Returns
Ensysce Biosciences secures Sharpe Ratio (or Efficiency) of -0.27, which denotes the company had a -0.27 % return per unit of risk over the last 3 months. Ensysce Biosciences exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Ensysce Biosciences' Mean Deviation of 3.75, variance of 25.9, and Standard Deviation of 5.09 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.02, which means a somewhat significant risk relative to the market. Ensysce Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Ensysce Biosciences is expected to follow. At this point, Ensysce Biosciences has a negative expected return of -1.36%. Please make sure to confirm Ensysce Biosciences' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Ensysce Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.66 |
Good predictability
Ensysce Biosciences has good predictability. Overlapping area represents the amount of predictability between Ensysce Biosciences time series from 26th of October 2025 to 10th of December 2025 and 10th of December 2025 to 24th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ensysce Biosciences price movement. The serial correlation of 0.66 indicates that around 66.0% of current Ensysce Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.66 | |
| Spearman Rank Test | 0.77 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Ensysce Biosciences reported net income of (7.99 Million). This is 102.34% lower than that of the Biotechnology sector and 111.4% lower than that of the Health Care industry. The net income for all United States stocks is 101.4% higher than that of the company.
Ensysce Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ensysce Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ensysce Biosciences could also be used in its relative valuation, which is a method of valuing Ensysce Biosciences by comparing valuation metrics of similar companies.Ensysce Biosciences is currently under evaluation in net income category among its peers.
Ensysce Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Ensysce Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ensysce Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ensysce Biosciences' value.| Shares | Perceptive Advisors Llc | 2025-06-30 | 86.7 K | Sabby Management Llc | 2025-06-30 | 0.0 | Adage Capital Partners Gp Llc | 2025-06-30 | 74.7 K | Geode Capital Management, Llc | 2025-06-30 | 10.2 K | Fny Investment Advisers, Llc | 2025-06-30 | 3 K | Sbi Securities Co Ltd | 2025-06-30 | 2.3 K | Tower Research Capital Llc | 2025-06-30 | 1.4 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 378 | Ubs Group Ag | 2025-06-30 | 354 | Blackrock Inc | 2025-06-30 | 65.0 | Bank Of America Corp | 2025-06-30 | 19.0 |
Ensysce Fundamentals
| Return On Equity | -2.94 | ||||
| Return On Asset | -1.1 | ||||
| Profit Margin | (2.44) % | ||||
| Operating Margin | (7.59) % | ||||
| Current Valuation | 1.95 M | ||||
| Shares Outstanding | 3.63 M | ||||
| Shares Owned By Insiders | 0.29 % | ||||
| Shares Owned By Institutions | 9.93 % | ||||
| Number Of Shares Shorted | 166.97 K | ||||
| Price To Book | 2.69 X | ||||
| Price To Sales | 0.72 X | ||||
| Revenue | 5.21 M | ||||
| Gross Profit | (6.08 M) | ||||
| EBITDA | (6.73 M) | ||||
| Net Income | (7.99 M) | ||||
| Cash And Equivalents | 3.15 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 301.66 K | ||||
| Debt To Equity | 6.91 % | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (7.5 T) | ||||
| Short Ratio | 0.40 X | ||||
| Earnings Per Share | (6.35) X | ||||
| Target Price | 19.23 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 3.23 M | ||||
| Total Asset | 5.6 M | ||||
| Retained Earnings | (129.54 M) | ||||
| Working Capital | 3.14 M | ||||
| Net Asset | 5.6 M |
About Ensysce Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ensysce Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ensysce Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ensysce Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:Check out Ensysce Biosciences Piotroski F Score and Ensysce Biosciences Altman Z Score analysis. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.35) | Revenue Per Share | Quarterly Revenue Growth (0.86) | Return On Assets | Return On Equity |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.